Press Releases for TEVA

Press Releases
Teva Announces Settlement in Principle regarding Certain Drug Pricing Lawsuits
Teva Announces FDA Accepts BLA for XM02
Flu season worse for those with asthma
Teva Receives Favorable Court Decision Regarding Generic Temodar®
Court of Appeals Affirms Favorable Decision Regarding Generic Prevacid® SoluTab
Teva Announces Tentative Approval of Generic Femara® Tablets
Analyst Choice Offers Latest Analysis of Financial, Healthcare and Technology Sectors
Teva-KOWA Pharma to Acquire a Majority Share Interest in Taisho Pharmaceutical Industries
Teva Receives Final Approval for Generic Prevacid® Delayed-Release Capsules
Teva Receives Favorable Court Decision Regarding Generic Prevacid® SoluTab
Market Watch: Sunwin International Neutraceuticals - November 10, 2009
Teva Files Amended Complaint Against Momenta/Sandoz to Include Infringement of Three COPAXONE®-Related Patents
Teva Introduces Fexofenadine HCl and Pseudoephedrine HCl Extended-Release Tablets; An Alternative to Allegra-D® 12 Hour Tablets
Teva Reports Third Quarter 2009 Results
MichBio Expo &Amp; Conference Exhibitors Profiled
Teva Comments on Mylan Paragraph IV Filing for COPAXONE®; Files Lawsuit Against Generic Filer for Patent Infringement
Lawyers target Israeli medical supplier
Teva Provides Update on Generic Seroquel® Litigation
Teva Provides Update on Generic Evista® Litigation
Teva Women's Health Announces CopewithMenopause.Com Relaunch Just in Time for Menopause Awareness Month ; New Design Features Dynamic Content Including Videos and Resources to Help Women and Their Families Deal With the Impact of Menopause
The First Israel Fund, Inc. Announces Performance Data and Portfolio Composition
Teva Provides Update on Generic Singulair® Litigation
StockPreacher.com Issues Trading Outlook for Cell Therapeutics Inc.
Bancroft Fund Ltd. Announces Earnings and Financial Update
Antares Pharma Reports Second Quarter 2009 Financial and Operating Results
Teva Announces Approval and Launch of Oxaliplatin Injection
Teva Announces Appeals Court Ruling Affirming Invalidation of Yasmin® Patent
Teva Announces Appeals Court Ruling Affirming Invalidation of Yasmin® Patent
Perrigo Announces FDA Approval for Generic Version of NASACORT(R) AQ
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
Compugen Reports Second Quarter 2009 Results
Teva Reports Second Quarter 2009 Results
Teva and Ortho-McNeil-Janssen Settle Ortho Tri-Cyclen® Lo Litigation
Teva and Ortho-McNeil-Janssen Settle Ortho Tri-Cyclen® Lo Litigation
Teva Provides Update on Generic Ortho Tri-Cyclen® Lo
Teva Provides Update on Generic Ortho Tri-Cyclen® Lo
Women underestimate menopause symptoms
Menopause Is More Than A Hot Flash
InvestorSoup.com Issues Trading Outlook for Hemispherex Biopharma Inc.
interCLICK Announces Appointment of Steven D. Rubin, Member of The Frost Group, LLC, To Advisory Board
Plan B® One-Step”New FDA-Approved One-Pill Emergency Contraceptive
Plan B® One-Step—New FDA-Approved One-Pill Emergency Contraceptive
FDA Approves Plan B® One-Step, a New One-Pill Emergency Contraceptive
FDA Approves Plan B® One-Step, a New One-Pill Emergency Contraceptive
Teva to Report Second Quarter 2009 Financial Results on July 28, 2009
Teva Provides Update on Generic Ortho Tri-Cyclen® Lo
Teva Provides Update on Generic Ortho Tri-Cyclen® Lo
Teva Announces Approval and Launch of Tri-Lo Sprintec Tablets
Compugen Reports Sale of a Portion of Its Evogene Holdings
Teva and Antares Announce FDA Approval of Needle-Free Injector Product for Administration of Tev-Tropin® (Human Growth Hormone)
Teva Completes Enrollment in Second Oral Laquinimod Phase III MS Clinical Trial
Teva Pharmaceuticals Issues Statement in Response to Federal Trade Commission Claims on Patent Settlements
Court Grants Teva Summary Judgment of Non-Infringement on Eloxatin®
Court Grants Teva Summary Judgment of Non-Infringement on Eloxatin®
Compugen Transfers to The NASDAQ Capital Market
Brinks Hofer Gilson & Lione Ranks Among the Top IP Law Firms in Illinois and U.S. According to Chambers 2009
Teva to Present at the Goldman Sachs 30th Annual Global Healthcare Conference
OPKO Health Completes Private Placement
Compugen Appoints Dr. Anat Cohen-Dayag and Martin Gerstel As Co-CEOs
Bancroft Fund Ltd. Announces Earnings and Financial Update
Healthcare Industry Is Not Unaffected By Economy
Teva to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fifth Annual Strategic Decisions Conference 2009
Federal Circuit Affirms Denial of Preliminary Injunction Regarding Teva's Generic Protonix® Tablets
Federal Circuit Affirms Denial of Preliminary Injunction Regarding Teva’s Generic Protonix® Tablets
Lonza and Teva Announce Receipt of Regulatory Approval
Teva Announces Approval and Launch of Generic Urso 250® and Urso Forte®
Teva Announces Approval and Launch of Generic Urso 250® and Urso Forte®
Teva Provides Update on Generic Actonel® Litigation
Teva Provides Update on Generic Actonel® Litigation
Teva Announces Presentations at Bank Conferences
Antares Pharma Reports First Quarter 2009 Financial and Operating Results
Compugen Reports First Quarter 2009 Financial Results
Ellsworth Fund Ltd. Announces Earnings and Financial Update
MaybachFinancial.Com Posts Free Analyst Report on EMKR, ERTS, TEVA and SONS
Teva Announces Extension of Patent Protection for Azilect®
Teva Announces Extension of Patent Protection for Azilect®
Teva Reports First Quarter 2009 Results
New Data Illustrate Novel Mechanism OF Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
New Data Illustrate Novel Mechanism of Action of Laquinimod, an Oral Compound for the Treatment of Multiple Sclerosis
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
Teva Comments on Generic Evista® Preliminary Injunction
Teva to Present New Data on Its Innovative Therapies for Multiple Sclerosis and Parkinson’s Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting
Lilly Reports Strong First-Quarter 2009 Results - Apr 20 2009 12:57PM
Lilly Reports Strong First-Quarter 2009 Results - Apr 20 2009 6:55AM
Teva Introduces First Generic Adderall XR® Capsules in the United States
Teva Announces Approval of Generic Yaz® Tablets
Teva Announces Approval of Generic Yaz® Tablets
Teva Announces Approval and Launch of Generic Topamax® Tablets - Business Wire
Teva Announces Approval and Launch of Generic Topamax® Tablets - Business Wire
Teva Announces Approval and Launch of Generic Topamax(R) Tablets
Teva Announces FDA Response to Citizen Petition
Teva and Medicis Announce Settlement Agreement
Teva Announces Approval and Launch of Generic Solodyn® Extended-Release Tablets
Teva Announces Approval and Launch of Generic Solodyn(R) Extended- Release Tablets
Study Demonstrates That QVAR® is More Likely to Achieve Successful Asthma Control with Less Exacerbations
Teva to Present at the Cowen and Company 29th Annual Healthcare Conference
Teva Applauds Historic Biotech Competition Legislation - Mar 11 2009 3:46PM
Teva Applauds Historic Biotech Competition Legislation - Mar 11 2009 1:02PM
Teva to Present at the Barclays Capital Global Healthcare Conference
COPAXONE® Approved By the FDA for Patients With a First Clinical Event Suggestive of Multiple Sclerosis